Nesfatin-1: Does it Have Therapeutic Potential for Cyclophosphamide-Induced Interstitial Cystitis?
Osmangazi Tıp Dergisi, cilt.48, sa.6, ss.1205-1214, 2026 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 48 Sayı: 6
- Basım Tarihi: 2026
- Doi Numarası: 10.20515/otd.2002131
- Dergi Adı: Osmangazi Tıp Dergisi
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.1205-1214
- Kütahya Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a clinical condition characterized by symptoms such as frequent urination, suprapubic or pelvic pain, and decreased urine output. Inflammation is a significant contributor to the pathophysiology of this disease. Recent research has also highlighted the potent anti-apoptotic and antioxidant properties of nesfatin-1(NES) which is a hypothalamic neuropeptide. This study aimed to investigate the anti-inflammatory, anti-apoptotic, and antioxidant effects of NES in a cyclophosphamide (CYP)-induced IC model in rats. In this study female Sprague Dawley rats (n=32) were randomly assigned to four groups: control, CYP, CYP+NES 5 μg/kg, and CYP+NES 10 μg/kg. BPS/IC was induced by administering a single intraperitoneal (i.p.) dose of 70 mg/kg of CYP every three days for 12 days. The effects of NES were assessed using behavioral tests, histological examination, histopathological analyses, and biochemical analyses of bladder tissue.NES at a dose of 5 μg/kg and 10 μg/kg significantly reduced bladder pain as measured by the von Frey test. It showed partially protective effects against CYP-induced BPS/IC as evidenced by reduced histological and histopathological damage to the bladder, by way of suppression of oxidative stress markers and a decrease in inflammatory burden. Notably, the 5 μg/kg dosage of NES proved to be more effective than the 10 μg/kg dosage.In summary, these preclinical findings suggest that NES holds promise as a therapeutic agent for the treatment of CYP-induced BPS/IC. Nonetheless, further preclinical and clinical investigations are warranted to substantiate its efficacy and safety.